What Is the Treatment of Carcinoid Syndrome? First-Line Management

Carcinoid syndrome management is directed at controlling flushing and diarrhoea, achieving normal u5-HIAA levels, and addressing tumour burden. A structured first-line approach exists to address all three goals simultaneously.

Clinical Goals

Maximal symptom control — including resolution of flushing and diarrhoea — ideally alongside normal u5-HIAA levels and control or reduction of tumour burden.

Treatment Approach (Partial Overview)

First-line management centres on somatostatin analogue (SSA) therapy. The specific formulation selected depends on the severity of symptoms at presentation.

The full regimen — including specific agents, formulations, and the approach for varying symptom severity — is available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

SSA, octreotide or lanreotide, are the mainstay of CS treatment.

DOI: 10.1111/jne.13146

View source ↗